Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBC Survival Study in Sickle Cell Disease
NCT04028700Phase 2Terminated
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Jan 2022
- Primary completion
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of red blood cells in sickle cell disease (SCD), sponsored by University of North Carolina at Chapel Hill. Started Jan 2022; status: terminated.
02
Drugs
red blood cells
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT04028700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04028700.